-- Greater than 16-Fold Improvement in Survival Compared to
Historical Control --
SEATTLE--(BUSINESS WIRE)--Feb. 15, 2018--
Omeros Corporation (NASDAQ: OMER) today announced new results from the
company’s ongoing Phase 2 study of OMS721 evaluating patients with
hematopoietic stem cell transplant-associated thrombotic microangiopathy
(HCT-TMA). The data demonstrate an increase in median overall survival
in HCT-TMA patients treated with OMS721 c...
-- EMA also reviewing Priority Medicines application for the drug in
SEATTLE--(BUSINESS WIRE)--Jan. 22, 2018--
Omeros Corporation (Nasdaq: OMER) announced today that the European
Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products
(COMP) issued a positive opinion on Omeros’ application for orphan drug
designation of OMS721 in the treatment of primary Immunoglobulin A
nephropathy (IgAN). OMS721 is Omeros’ lead human monoc...
-- Also Initiates OMS721 Phase 3 Program in HCT-TMA --
SEATTLE--(BUSINESS WIRE)--Jan. 3, 2018--
Omeros Corporation (Nasdaq: OMER) today announced that it has reached
agreement with the US Food and Drug Administration (FDA) on Omeros’
protocol for its Phase 3 clinical trial evaluating OMS721 in patients
with IgA nephropathy (IgAN). Patient enrollment is expected to begin
early next month.
The single Phase 3 trial is a randomized, double...